bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Business Wire•09/10/2026•11:37 ET
3
Key Highlights
- ➤$4 million gross proceeds closed through registered direct financing
- ➤980,072 warrants issued privately at $6.122 exercise price
- ➤Net proceeds target working capital, CyPath® Lung sales, and corporate purposes
- ➤Pre-funded warrants carry $0.007 exercise price; warrants require stockholder approval
bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that it has closed its previously announced registered direct offering of shares of common stock (or pre-funded warrants in lieu thereof) with an institutional investor at a purchase price of $6.122 (or $6.115 per pre-funded warrant), in a registered direct offering priced at-the-market under Nasdaq rules.
Get started
Create a free account to read the full story.